Skip to main content

Table 4 Susceptibility of gram-negative organisms isolated from cerebrospinal fluid specimen sources. TSN Database USA 2000–2002

From: Prevalence of antimicrobial resistance in bacteria isolated from central nervous system specimens as reported by U.S. hospital laboratories from 2000 to 2002

Organism

Antimicrobial

Total n

%Sa

%R

Escherichia coli

amikacin

164

98.8

0

 

ampicillin

267

44.2

54.7

 

aztreonam

137

96.4

1.5

 

cefotaxime

168

98.2

0

 

ceftazidime

210

98.1

1.4

 

ceftriaxone

180

97.8

0.6

 

gentamicin

260

93.5

5.4

 

levofloxacin

198

97.5

2.5

 

meropenem

76

100

0

 

piperacillin

188

50.0

38.8

 

TMP-SMXb

252

77.0

23.0

Pseudomonas aeruginosa

amikacin

184

92.9

4.9

 

aztreonam

133

67.7

15.0

 

cefotaxime

111

9.0

49.5

 

ceftazidime

236

80.1

11.0

 

ceftriaxone

116

6.0

61.2

 

gentamicin

251

80.9

11.2

 

levofloxacin

174

82.2

11.5

 

meropenem

97

84.5

10.3

 

piperacillin

198

82.8

17.2

 

TMP-SMX

128

0.8

99.2

Enterobacter cloacae

amikacin

160

98.8

0

 

ampicillin

229

2.2

91.7

 

aztreonam

147

65.3

26.5

 

cefotaxime

154

63.6

28.6

 

ceftazidime

196

67.3

29.6

 

ceftriaxone

184

70.7

25.0

 

gentamicin

227

95.2

4.8

 

levofloxacin

176

96.0

4.0

 

meropenem

79

100

0

 

piperacillin

168

64.9

28.0

 

TMP-SMX

220

93.2

6.8

Acinetobacter baumannii

amikacin

112

75.0

17.9

 

aztreonam

88

8.0

73.9

 

cefotaxime

102

21.6

54.9

 

ceftazidime

142

48.6

38.7

 

ceftriaxone

119

25.2

53.8

 

gentamicin

143

61.5

38.5

 

levofloxacin

106

53.8

43.4

 

meropenem

68

75.0

23.5

 

piperacillin

111

40.5

40.5

 

TMP-SMX

140

54.3

45.7

Klebsiella pneumoniae

amikacin

95

92.6

0

 

ampicillin

129

0

98.4

 

aztreonam

70

84.3

14.3

 

cefotaxime

94

87.2

3.2

 

ceftazidime

111

76.6

18.0

 

ceftriaxone

108

84.3

2.8

 

gentamicin

131

87.8

8.4

 

levofloxacin

98

88.8

9.2

 

meropenem

47

100

0

 

piperacillin

102

65.7

26.5

 

TMP-SMX

133

83.5

16.5

Serratia marcescens

amikacin

71

95.8

2.8

 

ampicillin

104

5.8

92.3

 

aztreonam

55

87.3

7.3

 

cefotaxime

70

80.0

8.6

 

ceftazidime

86

93.0

4.7

 

ceftriaxone

71

91.5

5.6

 

gentamicin

108

95.4

2.8

 

levofloxacin

80

98.8

1.3

 

meropenem

43

100

0

 

piperacillin

81

72.8

21.0

 

TMP-SMX

105

95.2

4.8

Enterobacter aerogenes

amikacin

60

100

0

 

ampicillin

87

5.7

87.4

 

aztreonam

42

73.8

11.9

 

cefotaxime

54

74.1

1.9

 

ceftazidime

78

73.1

17.9

 

ceftriaxone

63

84.1

1.6

 

gentamicin

81

100

0

 

levofloxacin

51

100

0

 

meropenem

22

100

0

 

piperacillin

64

68.8

14.1

 

TMP-SMX

85

100

0

Haemophilus influenzae

ampicillin

61

72.1

24.6

 

cefotaxime

27

100

-d

 

ceftazidime

NAc

NA

NA

 

ceftriaxone

54

100

-

 

levofloxacin

10

100

-

 

TMP-SMX

32

87.5

9.4

Klebsiella oxytoca

amikacin

37

100

0

 

ampicillin

52

3.8

86.5

 

aztreonam

34

76.5

17.6

 

cefotaxime

37

81.1

16.2

 

ceftazidime

44

81.8

18.2

 

ceftriaxone

45

84.4

13.3

 

gentamicin

51

96.1

3.9

 

levofloxacin

39

100

0

 

meropenem

23

100

0

 

piperacillin

38

73.7

21.1

 

TMP-SMX

51

80.4

19.6

  1. aNCCLS interpretation for susceptible (S) and resistant (R) according to NCCLS guidelines [8]bTMP-SMX – Trimethoprim-sulfamethoxazole cNA <5 organisms tested dDashed line indicates that NCCLS breakpoints do not currently exist to interpret results as resistant